Özdede, A.Ayan, G.Can, G.Bektaş, M.Akdoğan, N.Solak, E. ÖksümEngin, B.Yalıcı Armağan, B.Adisen, E. Özsoy2024-05-072024-05-0720230003-49671468-2060https:/dx.doi.org10.1136/annrheumdis-2023-eular.5663https://hdl.handle.net/20.500.12451/11792We assessed PASS and its difference between sexes (?2 test). Moreover, we performed two logistic regression models to assess which factors were associated with PASS “no”, in both sexes. Results: Two-hundred and forty-five patients were enrolled. Female less accepted their disease status, compared with male patients, PASS “no” was 49.1% vs 23.5%, (p<0.001) (Table1). The factor associated with a higher probability to have an unacceptable symptoms state was a higher disease activity (Table 2), both for male and female. In particular, for male patients, when DAPSA increases of 1 point, the probability to have a state of PASS “no” increases of 31% (OR 1.31, CI 95% 1.16-1.47), independently by age, disease durations, BMI and BSA. The same result was confirmed for female patients, but with a stronger association: when DAPSA increases of 1 points the probability to have a state of PASS “no” increase of 101% (OR 2.01, CI 95% 1.45-2.77), independently by age, disease durations, BMI, BSA and fibromyalgia. Moreover, fibromyalgia in female patients was not associated with PASS “no”eninfo:eu-repo/semantics/openAccessDiagnostic TestsPsoriatic ArthritisConference Object821796179710.1136/annrheumdis-2023-eular.5663WOS:001107398706097Q1